Schwab Hits Record $12T Assets as MaxCyte Navigates Biotech Rationalization
Key Takeaways
- Charles Schwab reported record-breaking 2025 results with $12 trillion in client assets and a 50% surge in adjusted EPS, signaling a powerful recovery in the brokerage sector.
- Conversely, life sciences firm MaxCyte is navigating a 15% revenue decline as cell therapy customers consolidate programs and reduce capital expenditures.
Mentioned
Key Intelligence
Key Facts
- 1Charles Schwab reached a record $12 trillion in total client assets, up 18% year-over-year.
- 2Schwab's adjusted EPS surged 50% to $4.87, exceeding the upper end of company guidance.
- 3MaxCyte total revenue fell 15% to $33 million in 2025 due to biotech program rationalization.
- 4MaxCyte's largest customer reduced purchases and leases by 15% during the year.
- 5Schwab's adjusted pretax profit margin expanded by 800 basis points to reach 52% in Q4.
- 6MaxCyte successfully reduced Q4 operating expenses by over 50%, from $19.3M to $9.0M.
| Metric | ||
|---|---|---|
| 2025 Total Revenue | $23.9 Billion | $33.0 Million |
| Revenue Growth (YoY) | +22% | -15% |
| Q4 Profit Margin | 52% (Pretax) | 78% (Gross) |
| Core Growth Driver | Net New Assets ($519B) | Installed Base (857 units) |
Who's Affected
Analysis
The final quarter of 2025 has revealed a stark divergence in the health of the financial services and life sciences sectors. While Charles Schwab (SCHW) demonstrated the power of scale and market recovery by crossing the $12 trillion client asset milestone, MaxCyte (MXCT) continues to grapple with a 'rationalization' phase in the cell therapy industry. This contrast highlights a broader market trend: financial giants are successfully capturing massive retail and institutional inflows, while the 'pick-and-shovel' providers for biotechnology are still feeling the burn of industry-wide belt-tightening and program consolidations.
Charles Schwab’s performance in 2025 was nothing short of a masterclass in operational leverage. The firm reported a record $23.9 billion in total net revenue, a 22% increase year-over-year, and a staggering 50% jump in adjusted earnings per share to $4.87. The most critical metric for the firm’s long-term health, Core Net New Assets (NNA), reached $519 billion—a 42% annual increase. This influx of capital, combined with an 18% growth in total client assets to $12 trillion, suggests that the 'cash sorting' headwinds that plagued the firm in 2023 and 2024 have largely abated. Schwab is now operating with a 52% adjusted pretax profit margin, an expansion of nearly 800 basis points that reflects both higher interest revenue and disciplined cost management.
The firm reported a record $23.9 billion in total net revenue, a 22% increase year-over-year, and a staggering 50% jump in adjusted earnings per share to $4.87.
Beyond the headline asset numbers, Schwab is seeing a significant shift in how its clients interact with the platform. Managed investing net flows grew 36% to nearly $70 billion, nearly quadrupling since 2022. This transition toward advisory and managed solutions provides Schwab with a more stable, recurring revenue stream compared to transactional trading. Furthermore, the firm’s banking arm is showing renewed strength, with bank lending balances hitting an all-time high of $58 billion. With a Tier 1 leverage ratio of 7.1%, Schwab is now positioned well above its internal targets, providing ample cushion for future capital returns or strategic investments.
In sharp contrast, MaxCyte’s Q4 results underscore the ongoing volatility in the cell engineering space. The company reported a 15% decline in total revenue for 2025, falling to $33 million. The primary driver of this contraction was a significant reduction in Strategic Platform License (SPL) program-related revenue, which plummeted from $6.1 million to $3.4 million. CEO Maher Masoud attributed this to a wave of program consolidation and rationalization among its customer base. Most notably, MaxCyte’s largest customer reduced its purchases and leases by 15% as it reorganized manufacturing and managed existing inventory. The loss of six SPL clinical programs in 2025 creates a $4 million headwind heading into 2026, suggesting that the path to recovery for biotech instrumentation remains long.
What to Watch
However, MaxCyte is not standing still. The company has aggressively restructured its operations, slashing fourth-quarter operating expenses from $19.3 million in 2024 to just $9.0 million in 2025. This cost discipline allowed the firm to improve its gross margin to 78% in the final quarter. While the revenue outlook for 2026 remains cautious—assuming no immediate improvement in industry demand—MaxCyte has successfully diversified its core business. SPL customers now contribute 47% of core revenue, down from 55%, as the company expands its reach into non-SPL segments and integrates its SecurDx assay services.
For investors, these two reports offer a clear signal. The financial services sector, led by dominant players like Schwab, is benefiting from a 'flywheel' effect where massive asset inflows drive higher margins and earnings power. Meanwhile, the life sciences tools sector is in a defensive posture. Companies like MaxCyte are focusing on internal efficiencies and 'weathering the storm' until the next cycle of biotech R&D spending begins. The key for MaxCyte will be its ability to maintain its installed base, which actually grew to 857 instruments, ensuring it is the partner of choice when clinical programs eventually ramp back up.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |